查看其它语言版本

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a patented portfolio of therapies to address significant unmet medical needs in the human and animal health markets. The company has a number of therapies targeting human conditions in various stages of development including two products in first-in-human Phase I trials: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions; RGSH4K is a human autologous personalised therapeutic cancer vaccine to treat a wide range of cancer types.

Furthermore, Regeneus is developing therapies to target acne and other inflammatory skin conditions in humans, in addition to musculoskeletal and oncology treatments for animals.

     

新闻

亚洲证券市场报告 2015年11月26日 - Regeneus Ltd (ASX:RGS)开始犬类癌症疫苗试验

🕔11/26/2015 10:13:55 AM 5972

Regeneus (ASX:RGS), 一家临床阶段再生医药公司,今天宣布开始其犬类癌症疫苗技术Kvax试验,结合化学疗法治疗犬类淋巴瘤。

阅读全文
###

28,875 公司背景浏览

  • 本页浏览人次: (过去7日: 63) (过去30日: 228) (自发布以来: 2887) 

金融股市 ASX:RGS

公司详细信息

    总部
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • 电话
  • +61-2-9499-8010 
  • 传真
  • +61-2-9499-8020 
  • 主要部门
  • 医疗-制药 
  • 支柱产业
  • 生物科技 
  • 主页
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

财务报告

社会化媒体